RxDoctor Payments Data

Victor Phan, DO

Orthopaedic Surgery · Houston, TXNPI 1174500979

Payments from drug & device makers

$2,887in general payments, 2019–2025

Across 63 payments — averaging $45.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Acumed LLC$321
  • Zimmer Biomet$174
  • AstraZeneca$125
  • Medinc Of Texas$112
  • Johnson & Johnson$103
  • plus $60 from 2 others

What the payments were for

  • Food & beverage$2,78797%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker(2 entities)45$1,992
Acumed LLC4$321
Zimmer Biomet2$174
AstraZeneca1$125
Medinc Of Texas4$112
Johnson & Johnson5$103
ERMI LLC1$41
Fidia Pharma USA Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,887 in reported general payments places this provider in the 35th percentile of 1,337 orthopaedic surgery providers in Texas.

See all orthopaedic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$288,013
Medicare patients
323
Services billed
2,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban40$9,106
Celecoxib478$8,589
Diclofenac Sodium298$8,311
Cephalexin186$4,422
Methylprednisolone482$3,267
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen286$3,024
Enoxaparin Sodium42$2,971
Meloxicam367$1,005
Tramadol Hcl153$962
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol14$870
Acetaminophen-CodeineAcetaminophen With Codeine59$741
Clindamycin Hcl30$568
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$171
Duloxetine Hcl15$158
Gabapentin11$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$103$9,10640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,337 orthopaedic surgery providers in Texas.

Other orthopaedic surgery in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →